SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
1-Year Est. Return
14.02%
1 Year Est. Return
+14.02%
AUM
$128M
AUM Growth
-$21.3M
(-14%)
Holding
99
Top Buys
| 1 | +$1.21M | |
| 2 | +$1.09M | |
| 3 | +$1.02M | |
| 4 |
RadNet
RDNT
|
+$994K |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$875K |
Top Sells
| 1 | +$2.59M | |
| 2 | +$2.16M | |
| 3 | +$1.49M | |
| 4 |
Sarepta Therapeutics
SRPT
|
+$1.34M |
| 5 |
Health Catalyst
HCAT
|
+$1.13M |
Sector Composition
| 1 | Healthcare | 99.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LENZ
1
LENZ Therapeutics
LENZ
$1.1B
| $25.1M | 19.56% |
977,245
|
|
||
2
Eli Lilly
LLY
$725B
| $7.78M | 6.05% |
9,416
-3,130
|
|
||
3
UnitedHealth
UNH
$330B
| $6.75M | 5.26% |
12,895
-1,730
|
|
||
4
Mineralys Therapeutics
MLYS
$3.43B
| $5.88M | 4.58% |
370,513
-10,370
|
|
||
|
CTNM
5
Contineum Therapeutics
CTNM
$311M
| $5.59M | 4.35% |
800,787
|
|
||
6
Johnson & Johnson
JNJ
$467B
| $3.62M | 2.81% |
21,800
-1,100
|
|
||
7
Gilead Sciences
GILD
$153B
| $3.59M | 2.79% |
32,020
-19,290
|
|
||
8
Amgen
AMGN
$163B
| $3.24M | 2.52% |
10,385
-2,165
|
|
||
9
AbbVie
ABBV
$410B
| $3.1M | 2.41% |
14,800
-4,000
|
|
||
10
Intuitive Surgical
ISRG
$164B
| $2.6M | 2.02% |
5,250
+2,200
|
|
||
11
Abbott
ABT
$225B
| $2.48M | 1.93% |
18,698
-5,700
|
|
||
12
Boston Scientific
BSX
$149B
| $2.44M | 1.9% |
24,226
-8,300
|
|
||
13
Merck
MRK
$216B
| $2.41M | 1.88% |
26,900
+2,400
|
|
||
14
Vertex Pharmaceuticals
VRTX
$107B
| $2.29M | 1.78% |
4,725
+1,055
|
|
||
15
Stryker
SYK
$146B
| $2.27M | 1.77% |
6,100
-300
|
|
||
16
Danaher
DHR
$149B
| $2.17M | 1.69% |
10,575
+3,300
|
|
||
17
Medtronic
MDT
$123B
| $2.14M | 1.67% |
23,850
-2,500
|
|
||
18
argenx
ARGX
$52.3B
| $1.84M | 1.43% |
3,103
-327
|
|
||
19
Regeneron Pharmaceuticals
REGN
$61.1B
| $1.76M | 1.37% |
2,773
-627
|
|
||
20
BioMarin Pharmaceuticals
BMRN
$10.2B
| $1.66M | 1.29% |
23,530
-5,870
|
|
||
21
Thermo Fisher Scientific
TMO
$205B
| $1.62M | 1.26% |
3,250
-1,500
|
|
||
22
BioNTech
BNTX
$26B
| $1.56M | 1.22% |
17,175
-1,775
|
|
||
23
Pfizer
PFE
$140B
| $1.51M | 1.18% |
59,650
-18,000
|
|
||
24
Alnylam Pharmaceuticals
ALNY
$64.4B
| $1.41M | 1.09% |
5,205
-3,095
|
|
||
25
AstraZeneca
AZN
$260B
| $1.38M | 1.07% |
18,790
+4,140
|
|